Propel Bio Management »

X4 Pharmaceuticals shares owned by Propel Bio Management

Quarter-by-quarter ownership of X4 Pharmaceuticals (XFOR) shares owned by Propel Bio Management from 13F filings

Historical chart of Propel Bio Management investment in X4 Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including X4 Pharmaceuticals held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in X4 Pharmaceuticals by Propel Bio Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $449k 535k 0.84

More positions owned by Propel Bio Management

Plains Gp Holdings Lp-cl Comm (PAGP)
Applied Therapeutics Comm (APLT)
Tscan Therapeutics Comm (TCRX)
Madrigal Pharmaceuticals Comm (MDGL)
Crinetics Pharmaceuticals In Comm (CRNX)
Fulcrum Therapeutics Comm (FULC)
Fidelity Inv Mmtrsy 1 680 Comm
Phathom Pharmaceuticals Comm (PHAT)
Day One Biopharmaceuticals I Comm (DAWN)
Ardelyx Comm (ARDX)
Athira Pharma Comm (ATHA)
Telesat Corp Comm (TSAT)
Simplify Enhanced Income Comm (HIGH)
Akero Therapeutics Comm (AKRO)
Vanguard Short-term Bond Comm (BSV)

View all positions for Propel Bio Management

Top funds holding X4 Pharmaceuticals

NEA Management Company
Vanguard Group
OrbiMed Advisors
Perceptive Advisors
Kingdon Capital Management
Citadel Advisors
Millennium Management
GSA Capital Partners
Point72 Asset Management
Schonfeld Strategic Advisors
Propel Bio Management
Barclays
Simplify Asset Management
Royce & Associates
Bank of New York Mellon

View all funds holding X4 Pharmaceuticals